Fadi Hassan

Dr. Fadi Hassan

Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
MNMohammad E. Naffaa
Mohammad E. Naffaa
FHFadi Hassan
Fadi Hassan
AGAvivit Golan-Cohen
Avivit Golan-Cohen
Eugene MerzonEugene Merzon
Eugene Merzon
IGIlan Green
Ilan Green
ZPZiv Paz
Ziv Paz

11 May 2023 in Life
Verified
Journal Article
Open access
PDF file
FHFadi Hassan
Fadi Hassan
HJHelana Jeries
Helana Jeries
MNMohammad E. Naffaa
Mohammad E. Naffaa
Behcet’s disease (BD) is a chronic, multi-systemic inflammatory disorder mainly characterized by recurrent oral and genital ulcers, skin lesions, and uveitis. As no pathognomonic laboratory test exists for BD, the diagnosis relies solely on clinical features. Over the years, great efforts have been invested in creating clinical diagnostic and classification criteria. The international study group criteria introduced in 1990 were the first true multinational set of criteria. Despite improving the ability to diagnose BD, these criteria still have limitations, including the inability to diagnose patients presenting without oral ulcers or presenting with rare manifestations of the disease. This led to the introduction of the international criteria for BD in 2013, which improved the sensitivity with minimal compromise on specificity. Despite the efforts made and as our understanding of the clinical manifestations of BD and genetic pathogenesis continue to evolve, efforts should be made to further enhance the currently accepted international classification criteria, perhaps by incorporating genetic testing (e.g., family history or HLA typing) as well as ethnic group-specific features.

1 January 2010 in World Journal of Emergency Surgery
Verified
Journal Article
Open access
PDF file
KHKamal S Hassan
Kamal S Hassan
HCHector I Cohen
Hector I Cohen
FHFadi Hassan
Fadi Hassan
SHShadi K Hassan
Shadi K Hassan
Spontaneous splenic rupture considered a relatively rare but life threatening. The three commonest causes of spontaneous splenic rupture are malignant hematological diseases, viral infections and local inflammatory and neoplastic disorders. We describe a unique and unusual case of inflammatory myofibroblastic tumor of the tail of pancreas presented with massively enlarged spleen and spontaneous splenic rupture.

5 February 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
FHFadi Hassan
Fadi Hassan
MNMohammad E. Naffaa
Mohammad E. Naffaa
ASAmir Saab
Amir Saab
CPChaim Putterman
Chaim Putterman
Cognitive impairment is frequently reported among anti-phospholipid syndrome (APS) patients as well as anti-phospholipid antibody (aPL) carriers, but it is less studied than other manifestations of this condition. Moreover, the exact prevalence of cognitive impairment in these patients has not been accurately determined, mainly due to inconsistency in the tools used to identify impairment, small sample sizes, and variability in the anti-phospholipid antibodies measured and positivity cutoffs. The notion of a direct pathogenic effect is supported by the observation that the higher the number of aPLs present and the higher the load of the specific antibody, the greater the risk of cognitive impairment. There is some evidence to suggest that besides the thrombotic process, inflammation-related pathways play a role in the pathogenesis of cognitive impairment in APS. The cornerstone treatments of APS are anti-coagulant and anti-thrombotic medications. These treatments have shown some favorable effects in reversing cognitive impairment, but solid evidence for the efficacy and safety of these treatments in the context of cognitive impairment is still lacking. In this article, we review the current knowledge regarding the epidemiology, pathophysiology, clinical associations, and treatment of cognitive impairment associated with APS and aPL positivity.

8 November 2024 in International Journal of Rheumatic Diseases
Verified
Journal Article
Open access
FHFadi Hassan
Fadi Hassan
WKWasim Khoury
Wasim Khoury
RDRula Daood
Rula Daood
ASAmir Saab
Amir Saab
MNMohammad E. Naffaa
Mohammad E. Naffaa
HJHelana Jeries
Helana Jeries
Background: Parvovirus B19 infection has been associated with various clinical entities including musculoskeletal manifestations and the development of different autoimmune diseases. The aim of our study is to examine the musculoskeletal manifestations associated with acute parvovirus B19 infection and the possible development of chronic autoimmune rheumatic diseases.Patients and Methods: Retrospective cohort study that included adult hospitalized patients diagnosed with an acute parvovirus B19 infection between 1 January 2021 and 1 February 2024. Subjects were followed‐up for 6–12 months after hospitalization aiming to identify patients who developed chronic autoimmune rheumatic diseases.Results: The study included 23 patients diagnosed with acute parvovirus B19 infection. Patients were predominantly females (16, 69.6%) with mean age at diagnosis of 39.3 ± 13.11 years. Most patients were Jewish (15, 65.2%). The two most common acute symptoms were fever (82.6%) and myalgia (56.5%). Polyarthritis was present only in three patients (13%) and all of them had wrists involvement. Anti‐nuclear antibodies and rheumatoid factor were the most common autoantibodies present with equal prevalence each (13%). Five patients were treated with prednisone during the acute phase (21%), two (8.7%) of them needed drug escalation and were subsequently treated with hydroxychloroquine and methotrexate. One patient developed systemic lupus erythematosus during the first 6 months of follow‐up.Conclusion: Musculoskeletal manifestations developing during acute parvovirus B19 are usually self‐limited with only a small minority of patients developing chronic autoimmune diseases. It is crucial to differentiate self‐limited manifestations related to acute parvovirus B19 from idiopathic autoimmune diseases aiming to avoid unnecessary immunosuppressive therapy.

19 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RDRula Daood
Rula Daood
FSFiras Sabbah
Firas Sabbah
AFAbdallah Fawaz
Abdallah Fawaz
FHFadi Hassan
Fadi Hassan
MNMohammad E. Naffaa
Mohammad E. Naffaa
Behçet’s syndrome (BS) is a chronic, relapsing inflammatory disease with multisystem involvement and prominent neutrophil activation. The neutrophil-to-lymphocyte ratio (NLR) has gained increasing attention as a potential surrogate marker for systemic inflammation. In this review we aimed to summarize and critically review the current evidence regarding the utility of NLR in BS, including its association with overall disease activity and specific organ involvement, as well as to explore its strengths and limitations as a clinical biomarker. NLR seems to be a simple, accessible, and cost-effective biomarker that can be elevated in Behçet’s syndrome and tends to be higher during active disease. Studies have demonstrated its consistent correlation with overall disease activity, as well as with specific manifestations such as mucocutaneous, ocular, vascular, and articular involvement. Moreover, NLR levels have been shown to decrease in response to anti-inflammatory treatments, supporting its potential utility in monitoring treatment effectiveness. Despite its seemingly cost-effective features, its routine integration into daily practice remains largely limited, mainly due to low specificity and the lack of standardized cut-off level. Further prospective studies are needed to assess its use in daily practice before it can be integrated into any disease activity score.